Raymond S, et al. - Using next-generation sequencing (NGS), the researchers identified patients harbouring minority resistant variants to nucleos(t)ide and non-nucleoside reverse transcriptase (RT) inhibitors and evaluated their influence on the virological response (VR). No impact was observed on the VR of the treatment-naive patients to a rilpivirine-based regimen with the minority resistant variants.